Quentin Lecocq

Title: The Innovations of Quentin Lecocq

Introduction

Quentin Lecocq is a notable inventor based in Ganshoren, Belgium. He has made significant contributions to the field of immunology, particularly through his innovative work on polypeptides that bind to human Programmed Death Ligand-1 (huPDL1). His research has important implications for medical applications, including diagnostics and therapeutics.

Latest Patents

Quentin Lecocq holds a patent for "Human PD-L1-binding immunoglobulins." This invention relates to polypeptides, specifically those comprising an immunoglobulin domain that binds to huPDL1. The applications of these polypeptides include their use as a medicament or as a diagnostic agent, such as an immunotracer. He has 1 patent to his name.

Career Highlights

Lecocq is affiliated with the Vrije Universiteit Brussel, where he conducts his research and development. His work is at the forefront of immunological studies, contributing to advancements in understanding immune responses and potential treatments for various diseases.

Collaborations

Quentin Lecocq collaborates with esteemed colleagues, including Jo Van Ginderachter and Geert Raes. These partnerships enhance the research output and foster innovation in their respective fields.

Conclusion

Quentin Lecocq's contributions to immunology through his patent on human PD-L1-binding immunoglobulins highlight his role as an influential inventor. His work continues to pave the way for advancements in medical diagnostics and therapeutics.